Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.74 |
| ▸ | CDK1 | P06493 | 4/20 | 0.74 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.74 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | AURKA | O14965 | 1/20 | 0.74 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.74 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.74 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.74 |
| ▸ | CDK2 | P24941 | 1/20 | 0.74 |
| ▸ | GSK3A | P49840 | 1/20 | 0.74 |
| ▸ | CDK7 | P50613 | 1/20 | 0.74 |
| ▸ | CDK9 | P50750 | 1/20 | 0.74 |
| ▸ | CCNH | P51946 | 1/20 | 0.74 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.74 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.74 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.74 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.74 |
| ▸ | DYRK3 | O43781 | 5/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10093418 | 1.00 | GSK3B (0.74) | GSK3BCDK1PRKCDCCNB1MAPK1 | |
| SCHEMBL497152 | 1.00 | GSK3B (0.74) | GSK3BCDK1PRKCDCCNB1MAPK1 | |
| SCHEMBL26092662 | 0.85 | GSK3B (1.00) | GSK3BCDK1PRKCDCCNB1MAPK1 | |
| SCHEMBL497544 | 0.84 | DYRK3 (0.80) | GSK3BCDK1PRKCDCCNB1MAPK1 | |
| SCHEMBL497545 | 0.84 | DYRK3 (0.80) | GSK3BCDK1PRKCDCCNB1MAPK1 | |
| SCHEMBL10093419 | 0.84 | DYRK3 (0.80) | GSK3BCDK1PRKCDCCNB1MAPK1 | |
| SCHEMBL13196997 | 0.83 | DYRK3 (0.68) | GSK3BCDK1PRKCDCCNB1MAPK1 | |
| SCHEMBL2787615 | 0.82 | DYRK3 (1.00) | GSK3BCDK1PRKCDCCNB1MAPK1 | |
| SCHEMBL2787614 | 0.82 | DYRK3 (1.00) | GSK3BCDK1PRKCDCCNB1MAPK1 | |
| SCHEMBL4377398 | 0.81 | HPGD (0.61) | GSK3BCDK1PRKCDCCNB1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648452-B1 | 2-IMINO-4-(THIO)OXO-5-POLYCYCLOVINYLAZOLINES FOR USE AS PI3 KINASE INHIBITORS | MERCK SERONO SA (CH) | 2009-07-22 | — | — | EP | claimed |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | MERCK SERONO SA (CH) | 2009-02-12 | — | — | US | claimed |
| US-20070021447-A1 | 2-Imino-4-(thio)oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-01-25 | — | — | US | claimed |
| US-8106214-B2 | 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as PI3 kinase inhibitors | MERCK SERONO SA (CH) | 2012-01-31 | — | — | US | disclosed |
| EP-1648452-B1 | 2-IMINO-4-(THIO)OXO-5-POLYCYCLOVINYLAZOLINES FOR USE AS PI3 KINASE INHIBITORS | MERCK SERONO SA (CH) | 2009-07-22 | — | — | EP | disclosed |
| US-20080306057-A1 | P13K Inhibitors for the Treatment of Endometriosis | LABORATORIES SERONO SA (CH) | 2008-12-11 | — | — | US | disclosed |
| EP-1931424-A2 | P13K INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007030360-A2 | P13K INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2007-03-15 | — | — | WO | disclosed |
| US-20070021447-A1 | 2-Imino-4-(thio)oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-01-25 | — | — | US | disclosed |
| EP-1648452-A1 | 2-IMINO-4-(THIO)OXO-5-POLYCYCLOVINYLAZOLINES FOR USE AS PI3 KINASE INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005011686-A1 | 2-IMINO-4-(THIO) OXO-5-POLY CYCLOVINYLAZOLINES FOR USE AS P13 KINASE IHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | PDPK1, PRKD3, PRKD1 | GSK3B 100/4885CDK1 40/4885PRKCD 12/4885 |
| US-20070021447-A1 | 2-Imino-4-(thio)oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors | PI4K2B, PI4KA, PTK2B | GSK3B 1117/4885CDK1 95/4885PRKCD 284/4885 |
| US-20080306057-A1 | P13K Inhibitors for the Treatment of Endometriosis | PDPK1, PIK3R4, MAP3K3 | GSK3B 126/4885CDK1 67/4885PRKCD 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.